

Attorney Docket No. Le A 33 965

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Bischoff, et al.

Serial No.: 10/070,963

Group No.: 1614

Filed: 06/28/2002

Examiner:

For: "Novel Combination for the Treatment of Sexual Dysfunction"

PATENT

RECEIVED

OCT 11 2002

TECH CENTER 1600/2900

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 10/8/02

Maureen Chappell
Signature of Person Certifying

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.


Respectfully submitted,

Reg. No. 41,670

Telephone: (203) 812-3964

Date: Oct. 7, 2002

Jerrie L. Chiu
Jerrie L. Chiu
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516



Form PTO-1449
(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Serial No.
10/070,963

Group Art Unit
1614

Filing Date
06/28/2002

Atty. Docket No.
Le A 33 965

SUPPLEMENTAL

INFORMATION DISCLOSURE CITATION

Applicant(s) Bischoff, et al.

RECEIVED

OCT 15 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

*		DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	U2	5	0	0	6	5	3	0	04/09/91	Angerbauer et al.	514	277	01/17/89
	U3	5	1	7	7	0	8	0	01/05/93	Angerbauer, et al.	514	277	11/26/91

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F5	0	4	6	3	7	5	6	02/01/92	EP				
	F6	0	5	2	6	0	0	4	03/02/93	EP				
	F7	9	9	1	1	2	6	3	11/03/99	WO				
	F8	0	4	9	1	2	2	6	24/06/92	EP				
	F9	0	7	0	2	5	5	5	11/03/98	EP				


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R5	Turko, I., Ballard, S., Francis, S., Corbin, J., "Inhibition of Cyclic GMP-Binding Cyclic GMP-Specific Phosphodiesterase (Type 5) by Sildenafil and Related Compounds", Molecular Pharmacology, <u>56</u> : 124-130 (1999)
R6	Trigo-Rocha, F., Aronson, W., Hohenfellner, M., Ignarro, L., Rajfer, J., Lue, T., "Nitric Oxide and cGMP: Mediators of Pelvic Nerve-Stimulated Erection in Dogs", Am. J. Physiol., <u>264</u> : H419-H422 (1993)
R7	Bush, P., Aronson, W., Buga, G., Rajfer, J., Ignarro, L., "Nitric Oxide Is A Potent Relaxant of Human and Rabbit Corpus Cavernosum", J. Urology, <u>147</u> : 1650-1655 (1992)
R8	Rajfer, J., Aronson, W., Bush, P., Dorey, F., Ignarro, L., "Nitric Oxide As a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission", N.E. J. Medicine, <u>326</u> : 90-94 (1992)
R9	Sohn, M., Kohler, H., Handt, S., Sikora, R., Bosshardt, R., Wein, F., Jakse, G., "The Role of Intracavernosal Eicosanoids and Endotheline During Drug-Induced Erections", Int. J. Impotence Res., <u>4</u> : Suppl. 2., A11

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**RECEIVED**

OCT 15 2002

TECH CENTER 1600/2900

	(1992)
R10	Murray, K., "Phosphodiesterase V _A Inhibitors", Drugs, News Perspectives, <u>6</u> : 150-156 (1993)
R11	Andersson, K., Wagner, G., "Physiology of Penile Erection", Physiological Reviews, <u>75</u> : 191-236 (1995)
R12	Meinhardt, W., Kropman, R., Vermeij, P., Lycklama a Nijeholt, A., Zwartendijk, J., "The Influence of Medication on Erectile Function", Int. J. of Impotence, <u>9</u> : 17-26 (1997)
R13	Beavo, J., Reifsnnyder, D., "Primary Sequence of Cyclic Nucleotide Phosphodiesterase Isozymes and the Design of Selective Inhibitors", TIPS Reviews, <u>11</u> : 150-155 (1990)
R14	Dujovne, C., "New Lipid Lowering Drugs and New Effects of Old Drugs", Curr. Opinions in Lipidology, <u>8</u> : 362-368 (1997)
R15	El-Sakka, A., Lin, C., Chui, R., Dahiya, R., Lue, T., "Effects of Diabetes on Nitric Oxide Synthase and Growth Factor Genes and Protein Expression in an Animal Model", Int. J. Impotence Research, <u>11</u> : 123-132 (1999)
R16	Srilatha, B., Adaikan, P., Ng, S., Arulkumaran, S., "Elevated Low-Density Lipoprotein Cholesterol (LDL-C) Enhances Pro-Erectile Neurotransmission in the Corpus Cavernosum", Int. J. Impotence Research, <u>11</u> : 159-165 (1999)
R17	Thompson, G., Naoumova, R., "New Prospects For Lipid-Lowering Drugs", Exp. Opin. Invest. Drugs, <u>7</u> : 715-727 (1998)
R18	Angerbauer, R., Bischoff, H., Steinke, W., Ritter, W., "BAY W 6228 Rivastatin", Drugs of the Future, <u>19</u> : 537-541 (1994)
R19	Takeda, K., "BAY-w-6228 Rivastatin", Drugs of the Future, <u>20</u> : 611 (1995)
R20	Takeda, K., "BAY-w-6228 Cerivastatin Sodium", Drugs of the Future, <u>21</u> : 642 (1996)
R21	Boolell, M., Allen, M., Ballard, S., Gepi-Attee, S., Muirhead, G., Naylor, A., Osterloh, I., Gingell, C., "Sildenafil: An Orally Active Type 5 Cyclic GMP-Specific Phosphodiesterase Inhibitor For the Treatment of Penile Erectile Dysfunction", Int. J. Impotence Research, <u>8</u> : 47-52 (1996)
R22	Manns, D., "HMG-CoA-Reduktase Hemmer Im Uberblick", Pharmazie in Unserer Zeit, <u>28</u> : 147-152 (1999)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.